EGFR VACCINE TRIAL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项由国家癌症研究所资助的研究，目的是研究EGFRvIII多肽疫苗在肿瘤表达肿瘤特异性抗原EGFRvIII的患者中的安全性和免疫学效果，这些患者的癌症复发或进展的风险很高。这包括卵巢癌、前列腺癌和胃癌的患者。这种多肽疫苗将以GM-CSF或KLH为佐剂进行注射，目的是：1)评估以EGFRvIII为基础的多肽疫苗免疫患者的安全性和潜在毒性；2)测定EGFRvIII多肽免疫后的EGFR特异性抗体反应水平；3)测定EGFRvIII多肽免疫后的EGFR特异性T细胞反应水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study funded by the National Cancer Institute to study the safety and immunologic efficacy of the EGFRvIII peptide vaccine in patients whose tumors express the tumor specific antigen EGFRvIII and who are at high risk for relapse or progression of their cancer. This includes patients with ovarian, prostate and stomach cancers. The peptide vaccine will be administered with GM-CSF or KLH as adjuvant in order to: 1) evaluate the safety and define the potential toxicity of immunizing patients with an EGFRvIII based peptide vaccine; 2) determine the level of EGFR specific antibody response after immunization with EGFRvIII peptide; and 3) determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide.